PIRS News and Press, Pieris Pharmaceuticals Inc. From 03/24/23

BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced tha...

Boston-based Pieris Pharmaceuticals ( NASDAQ: PIRS ) said it achieved a $5M milestone from Seagen after the Bothell, Wash.-based company dosed the first patient in a phase 1 trial of cancer drug SGN-BB228 (PRS-346). The Seagen-sponsored phase 1 study is evaluating the sa...

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other conditions, today announ...

BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today annou...

BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announ...

Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 ET Company Participants Thomas Bures - SVP & CFO Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Chief Development Officer Conference Ca...

The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Pieris Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q3 GAAP EPS of -$0.13 in-line. Revenue of $5.37M (+32.6% Y/Y) beats by $0.86M . Cash, cash equivalents, and investments totaled $69.8 million for the quarter ended September 30, 2022, compared to a cash and cas...

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDT Elarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continues First subject dosed in PRS-220 phase 1 study for idiopathic pulmonary fibrosis (IPF) PRS-344/S095012 phase 1 s...

BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...